ea0081oc3.2 | Oral Communications 3: Thyroid 1 | ECE2022
Durante Cosimo
, Brose Marcia
, Robinson Bruce
, Sherman Steven I
, Jarzab Barbara
, Lin Chia-Chi
, Vaisman Fernanda
, Hoff Ana O
, Hitre Erika
, Bowles Daniel W
, Sen Suvajit
, Patel Purvi
, Keam Bhumsuk
, Capdevila Jaume
Background: At a preplanned interim analysis (median follow-up 6.2 months) of the double-blind, phase 3 COSMIC-311 trial (NCT03690388), cabozantinib significantly improved progression-free survival (PFS) vs placebo (HR 0.22, 96% CI 0.13-0.36; P<0.0001) in 187 patients with previously treated radioiodine-refractory DTC (Brose, Lancet Oncol; 2021). Patients must have received lenvatinib or sorafenib and progressed during or after 1-2 prior VEGFR inhibitors. We prese...